GH1 and acromegaly: In a large, randomized, 12-month, Phase III core study in medically naïve patients with acromegaly, pasireotide long-acting release (LAR) was significantly superior (P = 0.007) to octreotide LAR at providing GH <2.5 μg/L and normal IGF-1 [16].